YARWNasdaqPharmaceutical PreparationsFiscal year ends December 31
Yarrow Bioscience, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$19.98+1.67 (+9.12%)
Close on Oct 19, 2026
- Market cap
- $17.14M
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Who owns Yarrow Bioscience's shares
Held by institutions
–
Shares held, 13F filers
Institutional holders
–
Net institutional buying
–
Insider trades, 12 months
0 buys · 0 sales
Open-market trades only
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Raymond Debbane | 675,000 | 7.20% | 13G (passive) | Sep 11, 2026 |
| ADAR1 Capital Management, LLC | 59,000 | 8.80% | 13G (passive) | Jun 30, 2026 |
| Logos Global Management GP LLC | 286,308 | 10.70% | 13G (passive) amendment | Jul 31, 2026 |
| venBio Global Strategic Fund V, L.P. | 279,340 | 9.99% | 13G (passive) | Jul 27, 2026 |
| Logos Global Management LP | 276,704 | 9.90% | 13G (passive) | Jul 27, 2026 |
| Perceptive Life Sciences Master Fund, Ltd. | 266,756 | 9.99% | 13G (passive) | Jul 27, 2026 |
| JANUS HENDERSON GROUP Ltd. | 266,712 | 9.99% | 13G (passive) | Jul 31, 2026 |
| RTW Fund Group GP, LLC | 266,307 | 9.99% | 13G (passive) | Jul 27, 2026 |
| Orbimed Advisors LLC | 266,306 | 9.97% | 13D (active) | Jul 27, 2026 |
| Daniel Mack | 2,000,000 | 6.00% | 13G (passive) | Mar 31, 2026 |
| Eventide Asset Management, LLC | 1,849,597 | 9.99% | 13G (passive) amendment | Jun 30, 2025 |
| Len Blavatnik | 178,180 | 6.02% | 13D (active) amendment | Jul 27, 2026 |
| Bellevue Asset Management AG | 1,000,000 | 10.60% | 13G (passive) | Sep 10, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Rebecca Frey | Chief Executive Officer, Director | – | – | Jul 29, 2026 |
| David Domzalski | PRESIDENT AND CEO, Director | 347,174 | 13.00% | Jul 24, 2026 |
| Lori Payton | Chief Development Officer | – | – | Jul 29, 2026 |
| Rachael Alford | Chief Operating Officer | – | – | Jul 29, 2026 |
| Steven Ryder | Chief Medical Officer | – | – | Jul 29, 2026 |
| Mutya Harsch | CHIEF LEGAL OFFICER AND GC | 95,918 | 3.59% | Jul 24, 2026 |
| Iain Stuart | CHIEF SCIENTIFIC OFFICER | 95,944 | 3.59% | Jul 24, 2026 |
| Mona Ashiya | Director | 33,287 | 1.25% | Jul 29, 2026 |
| Capital GP X. LLC OrbiMed | Director | – | – | Jul 29, 2026 |
| Genesis GP LLC OrbiMed | Director | – | – | Jul 29, 2026 |
| Steven L. Hoerter | Director | – | – | Jul 29, 2026 |
| Advisors Llc Orbimed | Director | 233,019 | 8.73% | Jul 29, 2026 |
| Tyler Zeronda | Director | 74,918 | 2.81% | Jul 29, 2026 |
| Peter B. Silverman | Director | – | – | Jul 29, 2026 |
| William Richard White | Director | – | – | Jul 29, 2026 |
| Sven Ante Lundberg | Director | – | – | Jul 29, 2026 |
| Elisabeth Sandoval Little | Director | – | – | Dec 15, 2025 |
| Steven L. Basta | Director | 853,942 | 31.99% | Dec 15, 2025 |
| Patrick G. Lepore | Director | 51,472 | 1.93% | Dec 15, 2025 |
| Sharon Barbari | Director | 75,000 | 2.81% | Dec 15, 2025 |
| Christine Borowski | Director | – | – | Dec 13, 2024 |
| Anthony D. Bruno | Director | 120,123 | 4.50% | Dec 13, 2024 |
| RTW Fund Group GP, LLC | 10% owner | 399,597 | 14.97% | Jul 30, 2026 |
| Roderick Wong | 10% owner | 266,307 | 9.97% | Jul 30, 2026 |
| Life Sciences Master Fund Ltd Perceptive | 10% owner | 5,435,057 | 203.58% | Jul 29, 2026 |
| Advisors Llc Perceptive | 10% owner | 266,309 | 9.98% | Jul 29, 2026 |
| Joseph Edelman | 10% owner | 4,935,057 | 184.85% | Jul 29, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Roderick Wong 10% owner | Jul 29, 2026 | Other | −133,290 | – | – | 266,307 |
| Mutya Harsch CHIEF LEGAL OFFICER AND GC | Jul 23, 2026 | Tax withholding | −22,516 | $0.90 | $20.26K | 95,918 |
| Iain Stuart CHIEF SCIENTIFIC OFFICER | Jul 23, 2026 | Tax withholding | −15,405 | $0.90 | $13.86K | 95,944 |
| Tyler Zeronda CHIEF FINANCIAL OFFICER | Jul 23, 2026 | Tax withholding | −22,516 | $0.90 | $20.26K | 74,918 |
| David Domzalski PRESIDENT AND CEO, Director | Jul 23, 2026 | Tax withholding | −79,391 | $0.90 | $71.45K | 347,174 |
| Tyler Zeronda CHIEF FINANCIAL OFFICER | Jun 30, 2026 | Tax withholding | −3,464 | $0.65 | $2.25K | 97,434 |
| Iain Stuart CHIEF SCIENTIFIC OFFICER | Jun 30, 2026 | Tax withholding | −2,370 | $0.65 | $1.54K | 111,349 |
| Mutya Harsch CHIEF LEGAL OFFICER AND GC | Jun 30, 2026 | Tax withholding | −3,464 | $0.65 | $2.25K | 118,434 |
| David Domzalski PRESIDENT AND CEO, Director | Jun 30, 2026 | Tax withholding | −12,214 | $0.65 | $7.94K | 426,565 |
| David Domzalski PRESIDENT AND CEO, Director | May 29, 2026 | Award | +30,791 | $0.31 | $9.55K | 438,779 |
| Mutya Harsch CHIEF LEGAL OFFICER AND GC | Mar 31, 2026 | Tax withholding | −4,007 | $0.60 | $2.40K | 121,898 |
| David Domzalski PRESIDENT AND CEO, Director | Mar 31, 2026 | Tax withholding | −14,232 | $0.60 | $8.54K | 401,976 |
| Tyler Zeronda CHIEF FINANCIAL OFFICER | Mar 31, 2026 | Tax withholding | −4,007 | $0.60 | $2.40K | 99,788 |
| Iain Stuart CHIEF SCIENTIFIC OFFICER | Mar 31, 2026 | Tax withholding | −2,876 | $0.60 | $1.73K | 112,363 |
| Mutya Harsch CHIEF LEGAL OFFICER AND GC | Dec 31, 2025 | Tax withholding | −3,579 | $0.58 | $2.08K | 125,905 |
| Iain Stuart CHIEF SCIENTIFIC OFFICER | Dec 31, 2025 | Tax withholding | −2,448 | $0.58 | $1.42K | 115,239 |
| David Domzalski PRESIDENT AND CEO, Director | Dec 31, 2025 | Tax withholding | −12,684 | $0.58 | $7.36K | 416,208 |
| Tyler Zeronda CHIEF FINANCIAL OFFICER | Dec 31, 2025 | Tax withholding | −7,858 | $0.58 | $4.56K | 103,795 |
| Iain Stuart CHIEF SCIENTIFIC OFFICER | Sep 30, 2025 | Tax withholding | −2,453 | $0.34 | $834 | 117,687 |
| Mutya Harsch CHIEF LEGAL OFFICER AND GC | Sep 30, 2025 | Tax withholding | −3,581 | $0.34 | $1.22K | 129,484 |
| Tyler Zeronda CHIEF FINANCIAL OFFICER | Sep 30, 2025 | Tax withholding | −3,420 | $0.34 | $1.16K | 111,653 |
| David Domzalski PRESIDENT AND CEO, Director | Sep 30, 2025 | Tax withholding | −12,676 | $0.34 | $4.31K | 428,892 |
| Tyler Zeronda CHIEF FINANCIAL OFFICER | Jun 30, 2025 | Tax withholding | −3,420 | $1.65 | $5.64K | 115,073 |
| David Domzalski PRESIDENT AND CEO, Director | Jun 30, 2025 | Tax withholding | −12,676 | $1.65 | $20.92K | 441,568 |
| Iain Stuart CHIEF SCIENTIFIC OFFICER | Jun 30, 2025 | Tax withholding | −2,453 | $1.65 | $4.05K | 120,140 |
| Mutya Harsch CHIEF LEGAL OFFICER AND GC | Jun 30, 2025 | Tax withholding | −3,581 | $1.65 | $5.91K | 133,065 |
| David Domzalski PRESIDENT AND CEO, Director | Jun 2, 2025 | Award | +8,681 | $0.81 | $7.03K | 454,244 |
| Mutya Harsch CHIEF LEGAL OFFICER AND GC | Jun 2, 2025 | Award | +1,145 | $0.81 | $927 | 136,646 |
| Mutya Harsch CHIEF LEGAL OFFICER AND GC | Mar 31, 2025 | Tax withholding | −8,828 | $1.58 | $13.95K | 135,501 |
| Tyler Zeronda CHIEF FINANCIAL OFFICER | Mar 31, 2025 | Tax withholding | −8,399 | $1.58 | $13.27K | 118,493 |
| David Domzalski PRESIDENT AND CEO, Director | Mar 31, 2025 | Tax withholding | −30,498 | $1.58 | $48.19K | 445,563 |
| Iain Stuart CHIEF SCIENTIFIC OFFICER | Mar 31, 2025 | Tax withholding | −6,044 | $1.58 | $9.55K | 122,593 |
| Patrick G. Lepore Director | Jan 15, 2025 | Buy | +15,000 | $2.92 | $43.80K | 51,472 |
| Mutya Harsch CHIEF LEGAL OFFICER AND GC | Dec 31, 2024 | Tax withholding | −4,697 | $3.35 | $15.73K | 144,329 |
| Tyler Zeronda CHIEF FINANCIAL OFFICER | Dec 31, 2024 | Tax withholding | −4,675 | $3.35 | $15.66K | 126,892 |
| Iain Stuart CHIEF SCIENTIFIC OFFICER | Dec 31, 2024 | Tax withholding | −4,857 | $3.35 | $16.27K | 128,637 |
| David Domzalski PRESIDENT AND CEO, Director | Dec 31, 2024 | Tax withholding | −24,536 | $3.35 | $82.20K | 476,061 |
| David Domzalski PRESIDENT AND CEO, Director | Nov 30, 2024 | Award | +3,901 | $2.10 | $8.19K | 500,597 |
| Tyler Zeronda CHIEF FINANCIAL OFFICER | Sep 30, 2024 | Tax withholding | −84 | $1.88 | $158 | 131,567 |
| Iain Stuart CHIEF SCIENTIFIC OFFICER | Sep 30, 2024 | Tax withholding | −109 | $1.88 | $205 | 133,494 |
| Mutya Harsch CHIEF LEGAL OFFICER AND GC | Sep 30, 2024 | Tax withholding | −105 | $1.88 | $197 | 149,026 |
| David Domzalski PRESIDENT AND CEO, Director | Sep 30, 2024 | Tax withholding | −685 | $1.88 | $1.29K | 496,696 |
| David Domzalski PRESIDENT AND CEO, Director | Jul 1, 2024 | Tax withholding | −935 | $1.92 | $1.80K | 497,654 |
| Iain Stuart CHIEF SCIENTIFIC OFFICER | Jul 1, 2024 | Tax withholding | −138 | $1.92 | $265 | 133,603 |
| Mutya Harsch CHIEF LEGAL OFFICER AND GC | Jul 1, 2024 | Tax withholding | −143 | $1.92 | $275 | 149,131 |
| Tyler Zeronda CHIEF FINANCIAL OFFICER | Jul 1, 2024 | Tax withholding | −92 | $1.92 | $177 | 131,651 |
| David Domzalski PRESIDENT AND CEO, Director | May 31, 2024 | Award | +4,429 | $2.16 | $9.57K | 498,589 |
| David Domzalski PRESIDENT AND CEO, Director | Apr 1, 2024 | Tax withholding | −1,004 | $3.08 | $3.09K | 494,160 |
| Mutya Harsch CHIEF LEGAL OFFICER AND GC | Apr 1, 2024 | Tax withholding | −161 | $3.08 | $496 | 149,274 |
| Iain Stuart CHIEF SCIENTIFIC OFFICER | Apr 1, 2024 | Tax withholding | −157 | $3.08 | $484 | 133,741 |
| Tyler Zeronda CHIEF FINANCIAL OFFICER | Apr 1, 2024 | Tax withholding | −94 | $3.08 | $290 | 131,743 |
| David Domzalski President and CEO, Director | Jan 2, 2024 | Tax withholding | −1,004 | $2.28 | $2.29K | 495,164 |
| Tyler Zeronda Chief Financial Officer | Jan 2, 2024 | Tax withholding | −93 | $2.28 | $212 | 131,837 |
| Iain Stuart Chief Scientific Officer | Jan 2, 2024 | Tax withholding | −157 | $2.28 | $358 | 133,898 |
| Mutya Harsch Chief Legal Officer and GC | Jan 2, 2024 | Tax withholding | −161 | $2.28 | $367 | 149,435 |
| David Domzalski President and CEO, Director | Jan 1, 2024 | Award | +225,000 | – | – | 496,168 |
| Tyler Zeronda Chief Financial Officer | Jan 1, 2024 | Award | +62,500 | – | – | 131,930 |
| Iain Stuart Chief Scientific Officer | Jan 1, 2024 | Award | +62,500 | – | – | 134,055 |
| Mutya Harsch Chief Legal Officer and GC | Jan 1, 2024 | Award | +62,500 | – | – | 149,596 |
| Tyler Zeronda Chief Financial Officer | Dec 13, 2023 | Award | +62,500 | – | – | 69,430 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.